

Testing of the Guidance on Risk Assessment of Living Modified Organisms

#43



COMPLETE

Collector: BCH website (Website Survey)

Started: Monday, March 31, 2014 9:26:41 PM

Last Modified: Monday, March 31, 2014 10:49:17 PM

Time Spent: 01:22:36

PAGE 1

Q1: Type of submission:

Party

PAGE 2

Q2: Name of the Party:

Philippines

Q3: Person submitting this questionnaire:

Full Name:

Julieta Fe L. Estacio

Email Address:

estaciojulietafe@gmail.com

Q4: Institution(s) or organization(s) that participated in the testing:

Government authority(ies)

Q5: Context in which the testing was conducted

Group event(s) (e.g., workshop, training course, meeting)

Q6: Actual case(s) of risk assessment used in the testing: Note: Please enter the hyperlinks of BCH Risk Assessment Records (e.g. <http://bch.cbd.int/database/record.shtml?documentid=104904> and <http://bch.cbd.int/database/record.shtml?documentid=104905>) or other publicly accessible web pages containing the technical and scientific data of the actual cases of risk assessment used in the testing.

Risk Assessment 1:

<http://biotech.da.gov.ph/Forms.php>(Application Form and Risk assessment form)

Q7: In what language was the Guidance tested?

English

PAGE 3

Q8: Name of the other Government:

Respondent skipped this question

Q9: Person submitting this questionnaire:

Respondent skipped this question

Q10: Institution(s) or organization(s) that participated in the testing:

Respondent skipped this question

Q11: Context in which the testing was conducted

Respondent skipped this question

Q12: Actual case(s) of risk assessment used in the testing: Note: Please enter the hyperlinks of BCH Risk Assessment Records (e.g. <http://bch.cbd.int/database/record.shtml?documentid=104904> and <http://bch.cbd.int/database/record.shtml?documentid=104905>) or other publicly accessible web pages containing the technical and scientific data of the actual cases of risk assessment used in the testing.

Respondent skipped this question

Q13: In what language was the Guidance tested?

Respondent skipped this question

PAGE 4

Q14: Name of the organization:	<i>Respondent skipped this question</i>
Q15: Person submitting this questionnaire:	<i>Respondent skipped this question</i>
Q16: Institution(s) or organization(s) that participated in the testing:	<i>Respondent skipped this question</i>
Q17: Context in which the testing was conducted	<i>Respondent skipped this question</i>
Q18: Actual case(s) of risk assessment used in the testing: Note: Please enter the hyperlinks of BCH Risk Assessment Records (e.g. http://bch.cbd.int/database/record.shtml?documentid=104904 and http://bch.cbd.int/database/record.shtml?documentid=104905) or other publicly accessible web pages containing the technical and scientific data of the actual cases of risk assessment used in the testing.	<i>Respondent skipped this question</i>
Q19: In what language was the Guidance tested?	<i>Respondent skipped this question</i>

PAGE 5

Q20: Would you like to submit an evaluation of the following section of the Guidance: Part I: The Roadmap for Risk Assessment	Yes
--	-----

PAGE 6

Q21: This section of the Guidance is practical.1 (no label)	Disagree
Q22: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:	<i>Respondent skipped this question</i>
Q23: This section of the Guidance is useful or has utility.2 (no label)	Neutral
Q24: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:	<i>Respondent skipped this question</i>
Q25: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3 (no label)	Disagree
Q26: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:	<i>Respondent skipped this question</i>

Testing of the Guidance on Risk Assessment of Living Modified Organisms

Q27: This section of the Guidance takes into account past and present experiences with LMOs.4

(no label)

Strongly Disagree

Q28: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:

OVERALL: experience over almost 20 years not considered (vector sequences, horizontal gene flow , chronic effects, bioaccumulation, persistence of gene product in environment). Please see attached

Q29: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

Respondent skipped this question

PAGE 7

Q30: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LMOs with stacked genes or traits

Yes

PAGE 8

Q31: This section of the Guidance is practical.1

(no label)

Disagree

Q32: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q33: This section of the Guidance is useful or has utility.2

(no label)

Disagree

Q34: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q35: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3

(no label)

Disagree

Q36: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q37: This section of the Guidance takes into account past and present experiences with LMOs.4

(no label)

Disagree

Q38: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:

OVERALL: experience over almost 20 years not considered (vector sequences, horizontal gene flow , chronic effects, bioaccumulation, persistence of gene product in environment). Please see attached

Q39: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

Respondent skipped this question

PAGE 9

Q40: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LM crops with tolerance to abiotic stress Yes

PAGE 10

Q41: This section of the Guidance is practical.1

(no label) Disagree

Q42: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q43: This section of the Guidance is useful or has utility.2

(no label) Disagree

Q44: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q45: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3

(no label) Disagree

Q46: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q47: This section of the Guidance takes into account past and present experiences with LMOs.4

(no label) Neutral

Q48: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q49: Here you may provide further details to explain your answers in evaluating this section of the Guidance: *Respondent skipped this question*

PAGE 11

Q50: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LM mosquitoes Yes

PAGE 12

Testing of the Guidance on Risk Assessment of Living Modified Organisms

Q51: This section of the Guidance is practical.1

(no label)

Neutral

Q52: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q53: This section of the Guidance is useful or has utility.2

(no label)

Neutral

Q54: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q55: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3

(no label)

Neutral

Q56: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q57: This section of the Guidance takes into account past and present experiences with LMOs.4

(no label)

Neutral

Q58: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q59: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

Respondent skipped this question

PAGE 13

Q60: Would you like to submit an evaluation of the following section of the Guidance: Part II: Specific types of LMOs or Traits - Risk assessment of LM trees

Yes

PAGE 14

Q61: This section of the Guidance is practical.1

(no label)

Neutral

Q62: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q63: This section of the Guidance is useful or has utility.2

(no label)

Neutral

Testing of the Guidance on Risk Assessment of Living Modified Organisms

Q64: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q65: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3

(no label)

Neutral

Q66: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q67: This section of the Guidance takes into account past and present experiences with LMOs.4

(no label)

Neutral

Q68: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q69: Here you may provide further details to explain your answers in evaluating this section of the Guidance: *Respondent skipped this question*

PAGE 15

Q70: Would you like to submit an evaluation of the following section of the Guidance: Part III: Monitoring of LMOs Released into the Environment Yes

PAGE 16

Q71: This section of the Guidance is practical.1

(no label)

Disagree

Q72: Would you like to suggest improvements to this section to increase its practicality? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q73: This section of the Guidance is useful or has utility.2

(no label)

Disagree

Q74: Would you like to suggest improvements to this section to increase its usefulness/utility? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Q75: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.3

(no label)

Disagree

Q76: Would you like to suggest improvements to this section to increase its consistency with the Protocol? If so, please indicate the line numbers and explain which improvements could be made: *Respondent skipped this question*

Testing of the Guidance on Risk Assessment of Living Modified Organisms

Q77: This section of the Guidance takes into account past and present experiences with LMOs.⁴

(no label)

Disagree

Q78: Would you like to suggest improvements to this section in order to better take into account past and present experiences with LMOs? If so, please indicate the line numbers and explain which improvements could be made:

Respondent skipped this question

Q79: Here you may provide further details to explain your answers in evaluating this section of the Guidance:

Respondent skipped this question

PAGE 17

Q80: Would you like to submit an evaluation of the following section of the Guidance: Background Documents

No

PAGE 18

Q81: This section of the Guidance is practical.¹

Respondent skipped this question

Q82: This section of the Guidance is useful or has utility.²

Respondent skipped this question

Q83: This section of the Guidance is consistent with the Cartagena Protocol on Biosafety.³

Respondent skipped this question

Q84: This section of the Guidance takes into account past and present experiences with LMOs.⁴

Respondent skipped this question

PAGE 19

Q85: Please use the space below if you wish to provide additional feedback regarding the testing of the Guidance on Risk Assessment of Living Modified Organisms:

Respondent skipped this question